COMMUNIQUÉS West-GlobeNewswire

Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study
16/03/2018
FREMONT, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ: ZSAN ) (“Zosano” or the “Company”) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of [...]
Collegium to Present at Upcoming Investor Conferences
16/03/2018
CANTON, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL ) today announced that management will present at the following investor conferences in March: The Oppenheimer & Company [...]
iCAD to Report Fourth Quarter and Fiscal 2017 Financial Results on Thursday, March 22, 2018
16/03/2018
NASHUA, N.H., March 16, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD ), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment [...]
Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
16/03/2018
BOSTON, March 16, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ) today announced that President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD, will present at the upcoming 17th [...]
Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018
16/03/2018
NEW YORK and LONDON, March 16, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan [...]
Progressive Care Reports 18% Increase in Year over Year Prescriptions Filled During February 2018
16/03/2018
MIAMI, March 16, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a healthcare services and technology company, announces strong sales for the month of February 2018. PharmCo, LLC filled over 19,500 [...]
OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology
16/03/2018
Study of 11,506 men shows that healthy men with an abnormal PSA and a low 4Kscore test result can be safely monitored rather than undergo prostate biopsy MIAMI, March 16, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ( [...]
Atara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
16/03/2018
Post-transplant lymphoproliferative disorder (PTLD) following allogeneic hematopoietic cell transplant (HCT) is an aggressive disease impacting a young population and carrying a significant mortality rate in a [...]
Fortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
16/03/2018
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO ) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results
16/03/2018
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the [...]
Kura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference
16/03/2018
SAN DIEGO, March 16, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA ), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its [...]
Xbrane Biopharma: Comment to call for an extraordinary general meeting
16/03/2018
Press release 2018-03-16 Xbrane Biopharma hereby calls for an extraordinary general meeting on Tuesday, April 3, 2018 at. 17.30 in Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm. The reason for the call for [...]
Xbrane Biopharma AB: Notice of extra general meeting in Xbrane Biopharma AB
16/03/2018
Press release 2018-03-16 The shareholders of Xbrane Biopharma AB, reg. no. 556749-2375, (the "Company"), are hereby convened to an extra general meeting to be held on Tuesday 3 April 2018, at 17.30 p.m. at [...]
TearLab Corporation Announces Voluntary Delisting From Toronto Stock Exchange
16/03/2018
SAN DIEGO, March 16, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX: TLB ) (“TearLab” or the “Company”) today announced that it has applied and received approval for a voluntary delisting of its common [...]
Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I Trial
16/03/2018
SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]
Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights
16/03/2018
- Positive topline results from pivotal LEAP 1 trial announced in September 2017, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $86.9 million cash and investments as of December 31 [...]
Cannabis Wheaton Income Corp. Provides Update on the Initial Development of FV Pharma Inc. Facility
16/03/2018
VANCOUVER, British Columbia, March 16, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX.V:CBW) (" Cannabis Wheaton " or the " Company ") is pleased to provide an update on the initial development of its [...]
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28
16/03/2018
COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in [...]
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
16/03/2018
Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered [...]

Pages